Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Patient-specific organotypic blood vessels as an in vitro model for anti-angiogenic drug response testing in renal cell carcinoma.

Jiménez-Torres JA, Virumbrales-Muñoz M, Sung KE, Lee MH, Abel EJ, Beebe DJ.

EBioMedicine. 2019 Apr;42:408-419. doi: 10.1016/j.ebiom.2019.03.026. Epub 2019 Mar 20.

2.

Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro.

Nguyen DH, Stapleton SC, Yang MT, Cha SS, Choi CK, Galie PA, Chen CS.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6712-7. doi: 10.1073/pnas.1221526110. Epub 2013 Apr 8.

4.

A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery.

Evensen L, Micklem DR, Link W, Lorens JB.

Cytometry A. 2010 Jan;77(1):41-51. doi: 10.1002/cyto.a.20808.

5.

Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy.

Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM.

Am J Pathol. 2003 Jan;162(1):183-93.

6.

Pro-angiogenic activity of notoginsenoside R1 in human umbilical vein endothelial cells in vitro and in a chemical-induced blood vessel loss model of zebrafish in vivo.

Yang BR, Hong SJ, Lee SM, Cong WH, Wan JB, Zhang ZR, Zhang QW, Zhang Y, Wang YT, Lin ZX.

Chin J Integr Med. 2016 Jun;22(6):420-9. doi: 10.1007/s11655-014-1954-8. Epub 2014 Dec 22.

PMID:
25533511
7.

Gene expression analysis in human breast cancer associated blood vessels.

Jones DT, Lechertier T, Mitter R, Herbert JM, Bicknell R, Jones JL, Li JL, Buffa F, Harris AL, Hodivala-Dilke K.

PLoS One. 2012;7(10):e44294. doi: 10.1371/journal.pone.0044294. Epub 2012 Oct 2.

8.

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.

Kuczynski EA, Yin M, Bar-Zion A, Lee CR, Butz H, Man S, Daley F, Vermeulen PB, Yousef GM, Foster FS, Reynolds AR, Kerbel RS.

J Natl Cancer Inst. 2016 Apr 8;108(8). doi: 10.1093/jnci/djw030. Print 2016 Aug.

9.

Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors.

Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM.

Am J Pathol. 2003 Nov;163(5):1801-15.

10.

A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs.

Pauty J, Usuba R, Cheng IG, Hespel L, Takahashi H, Kato K, Kobayashi M, Nakajima H, Lee E, Yger F, Soncin F, Matsunaga YT.

EBioMedicine. 2018 Jan;27:225-236. doi: 10.1016/j.ebiom.2017.12.014. Epub 2017 Dec 20. Erratum in: EBioMedicine. 2018 Feb 2;:.

12.

The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.

Li D, Finley SD.

Integr Biol (Camb). 2018 Apr 23;10(4):253-269. doi: 10.1039/c8ib00019k.

PMID:
29623971
13.

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.

Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR.

J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845. Epub 2016 Dec 29.

14.

A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.

Özcetin A, Aigner A, Bakowsky U.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):711-5. doi: 10.1016/j.ejpb.2013.07.010. Epub 2013 Jul 24.

PMID:
23891770
15.

Heterogeneity of tumor endothelial cells and drug delivery.

Hida K, Maishi N, Sakurai Y, Hida Y, Harashima H.

Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):140-147. doi: 10.1016/j.addr.2015.11.008. Epub 2015 Nov 26. Review.

PMID:
26626622
16.

Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies.

Bussolati B, Deregibus MC, Camussi G.

Curr Vasc Pharmacol. 2010 Mar;8(2):220-32. Review.

PMID:
19485921
17.

Broad targeting of angiogenesis for cancer prevention and therapy.

Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilsland A, Keith WN, Jensen LD.

Semin Cancer Biol. 2015 Dec;35 Suppl:S224-S243. doi: 10.1016/j.semcancer.2015.01.001. Epub 2015 Jan 16. Review.

18.

The biologic basis of in vivo angiogenesis imaging.

Ocak I, Baluk P, Barrett T, McDonald DM, Choyke P.

Front Biosci. 2007 May 1;12:3601-16. Review.

PMID:
17485324
19.

Tumor angiogenesis--characteristics of tumor endothelial cells.

Hida K, Maishi N, Torii C, Hida Y.

Int J Clin Oncol. 2016 Apr;21(2):206-212. doi: 10.1007/s10147-016-0957-1. Epub 2016 Feb 15. Review.

PMID:
26879652
20.

Supplemental Content

Support Center